{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:18:01Z","timestamp":1769019481746,"version":"3.49.0"},"reference-count":57,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Fundo de Financiamento da Investiga\u00e7\u00e3o da ULS S\u00e3o Jos\u00e9","award":["FFI31\/2024"],"award-info":[{"award-number":["FFI31\/2024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>With the approval of tolvaptan as the first specific medicine for the treatment of rapidly progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD), biomarker discovery has gained renewed interest as it is widely recognized that these will be crucial in clinical decision-making, serving as either prognostic or predictive tools. Since the marketing authorization was first issued in 2015 for ADPKD, tolvaptan has remained the sole pharmacological compound specifically targeting the disease. For ADPKD patients it is an invaluable medicine for retarding disease progression. Although the field of overall biomarker discovery and validation has been detailed in several publications, the role of inflammation remains largely overlooked in ADPKD. The current work aims to provide the reader with an updated review of inflammation biomarkers research in ADPKD, highlighting the role of urinary MCP-1 (monocyte chemoattractant protein-1) as the most promising tool.<\/jats:p>","DOI":"10.3390\/ijms26031121","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T06:47:29Z","timestamp":1738046849000},"page":"1121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Autosomal Dominant Polycystic Kidney Disease Inflammation Biomarkers in the Tolvaptan Era"],"prefix":"10.3390","volume":"26","author":[{"given":"T\u00e2nia","family":"Lap\u00e3o","sequence":"first","affiliation":[{"name":"Unidade Local de Sa\u00fade S\u00e3o Jos\u00e9, Servi\u00e7o de Patologia Cl\u00ednica, Centro Cl\u00ednico Acad\u00e9mico de Lisboa, 1150-199 Lisboa, Portugal"},{"name":"ToxOmics, NOVA Medical School, Universidade Nova de Lisboa, 1150-082 Lisbon, Portugal"}]},{"given":"Rui","family":"Barata","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade S\u00e3o Jos\u00e9, Servi\u00e7o de Nefrologia, Centro Cl\u00ednico Acad\u00e9mico de Lisboa, 1069-166 Lisboa, Portugal"}]},{"given":"Cristina","family":"Jorge","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade S\u00e3o Jos\u00e9, Servi\u00e7o de Nefrologia, Centro Cl\u00ednico Acad\u00e9mico de Lisboa, 1069-166 Lisboa, Portugal"}]},{"given":"Carlos","family":"Flores","sequence":"additional","affiliation":[{"name":"Unidade Local de Sa\u00fade S\u00e3o Jos\u00e9, Servi\u00e7o de Patologia Cl\u00ednica, Centro Cl\u00ednico Acad\u00e9mico de Lisboa, 1150-199 Lisboa, Portugal"}]},{"given":"Joaquim","family":"Calado","sequence":"additional","affiliation":[{"name":"ToxOmics, NOVA Medical School, Universidade Nova de Lisboa, 1150-082 Lisbon, Portugal"},{"name":"Unidade Local de Sa\u00fade S\u00e3o Jos\u00e9, Servi\u00e7o de Nefrologia, Centro Cl\u00ednico Acad\u00e9mico de Lisboa, 1069-166 Lisboa, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","article-title":"Autosomal dominant polycystic kidney disease","volume":"393","author":"Alam","year":"2019","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"iv15","DOI":"10.1093\/ndt\/gfu017","article-title":"Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: Prevalence and survival--an analysis of data from the ERA-EDTA Registry","volume":"29","author":"Spithoven","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1093\/ndt\/gfv456","article-title":"Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: A position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice","volume":"31","author":"Gansevoort","year":"2016","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/ndt\/gfab312","article-title":"An update on the use of tolvaptan for autosomal dominant polycystic kidney disease: Consensus statement on behalf of the ERA Working Group on Inherited Kidney Disorders, the European Rare Kidney Disease Reference Network and Polycystic Kidney Disease International","volume":"37","author":"Messchendorp","year":"2022","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e138724","DOI":"10.1172\/jci.insight.138724","article-title":"The value of genotypic and imaging information to predict functional and structural outcomes in ADPKD","volume":"5","author":"Lavu","year":"2020","journal-title":"JCI Insight"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1681\/ASN.2012070650","article-title":"Type of PKD1 mutation influences renal outcome in ADPKD","volume":"24","author":"Chen","year":"2013","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease","volume":"377","author":"Torres","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1681\/ASN.2018060590","article-title":"A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan","volume":"29","author":"Chebib","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an orally active vasopressin V(2)-receptor antagonist\u2014Pharmacology and clinical trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1038\/s41401-024-01325-5","article-title":"Structural basis of tolvaptan binding to the vasopressin V2 receptor","volume":"45","author":"Liu","year":"2024","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_16","unstructured":"(2016). Biomarkers, EndpointS, and Other Tools, Resource [Internet]."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/j.akdh.2022.12.009","article-title":"Biomarkers in Polycystic Kidney Disease: Are We There?","volume":"30","author":"Yu","year":"2023","journal-title":"Adv. Kidney Dis. Health"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of Disease: Autosomal dominant and recessive polycystic kidney diseases","volume":"2","author":"Torres","year":"2006","journal-title":"Nat. Clin. Pr. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1210\/jc.2007-0232","article-title":"Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects","volume":"92","author":"Szinnai","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2215\/CJN.08690813","article-title":"Kidney function and plasma copeptin levels in healthy kidney donors and autosomal dominant polycystic kidney disease patients","volume":"9","author":"Zittema","year":"2014","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.04560510","article-title":"Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease","volume":"6","author":"Meijer","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2013.08.007","article-title":"Apelin and copeptin: Two opposite biomarkers associated with kidney function decline and cyst growth in autosomal dominant polycystic kidney disease","volume":"49","author":"Lacquaniti","year":"2013","journal-title":"Peptides"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1681\/ASN.2016040448","article-title":"Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial","volume":"28","author":"Devuyst","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"204","DOI":"10.2215\/CJN.10470620","article-title":"Use of the Urine-to-Plasma Urea Ratio to Predict ADPKD Progression","volume":"16","author":"Heida","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Pana, C., Stanigut, A.M., Cimpineanu, B., Alexandru, A., Salim, C., Nicoara, A.D., Resit, P., and Tuta, L.A. (2023). Urinary Biomarkers in Monitoring the Progression and Treatment of Autosomal Dominant Polycystic Kidney Disease-The Promised Land?. Medicine (Kaunas), 59.","DOI":"10.3390\/medicina59050915"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/00000441-200510000-00002","article-title":"Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease","volume":"330","author":"Nakamura","year":"2005","journal-title":"Am. J. Med. Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","article-title":"Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: A cross-sectional analysis","volume":"56","author":"Meijer","year":"2010","journal-title":"Am. J. Kidney Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/j.akdh.2023.03.001","article-title":"Mechanisms of Cyst Development in Polycystic Kidney Disease","volume":"30","author":"Qiu","year":"2023","journal-title":"Adv. Kidney Dis. Health"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/ki.2008.686","article-title":"Incompletely penetrant PKD1 alleles suggest a role for gene dosage in cyst initiation in polycystic kidney disease","volume":"75","author":"Rossetti","year":"2009","journal-title":"Kidney Int."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1056\/NEJM199307293290508","article-title":"Autosomal dominant polycystic kidney disease","volume":"329","author":"Gabow","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41588-021-00946-4","article-title":"Renal plasticity revealed through reversal of polycystic kidney disease in mice","volume":"53","author":"Dong","year":"2021","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1172\/JCI45161","article-title":"Cellular pathophysiology of ischemic acute kidney injury","volume":"121","author":"Bonventre","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"109648","DOI":"10.1016\/j.cellsig.2020.109648","article-title":"Molecular pathways involved in injury-repair and ADPKD progression","volume":"72","author":"Formica","year":"2020","journal-title":"Cell Signal"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1681\/ASN.2018080810","article-title":"Tissue-Resident Macrophages Promote Renal Cystic Disease","volume":"30","author":"Zimmerman","year":"2019","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/ki.1992.413","article-title":"Renal histology in polycystic kidney disease with incipient and advanced renal failure","volume":"42","author":"Zeier","year":"1992","journal-title":"Kidney Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/nri2448","article-title":"Exploring the full spectrum of macrophage activation","volume":"8","author":"Mosser","year":"2008","journal-title":"Nat. Rev. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/jir.2008.0027","article-title":"Monocyte chemoattractant protein-1 (MCP-1): An overview","volume":"29","author":"Deshmane","year":"2009","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1046\/j.1523-1755.2001.00065.x","article-title":"Increased renal expression of monocyte chemoattractant protein-1 and osteopontin in ADPKD in rats","volume":"60","author":"Cowley","year":"2001","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/sj.ki.5002627","article-title":"Overexpression of innate immune response genes in a model of recessive polycystic kidney disease","volume":"73","author":"Mrug","year":"2008","journal-title":"Kidney Int."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1681\/ASN.2011010084","article-title":"Macrophages promote cyst growth in polycystic kidney disease","volume":"22","author":"Karihaloo","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1681\/ASN.2018050518","article-title":"Mcp1 Promotes Macrophage-Dependent Cyst Expansion in Autosomal Dominant Polycystic Kidney Disease","volume":"29","author":"Cassini","year":"2018","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000369149","article-title":"Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease","volume":"129","author":"Zoja","year":"2015","journal-title":"Nephron"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ki.1991.87","article-title":"Cytokines in fluids from polycystic kidneys","volume":"39","author":"Gardner","year":"1991","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"F204","DOI":"10.1152\/ajprenal.00470.2018","article-title":"Identifying cystogenic paracrine signaling molecules in cyst fluid of patients with polycystic kidney disease","volume":"316","author":"Kenter","year":"2019","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/MOH.0000000000000389","article-title":"The regulation and importance of monocyte chemoattractant protein-1","volume":"25","author":"Bianconi","year":"2018","journal-title":"Curr. Opin. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1172\/JCI80467","article-title":"Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease","volume":"125","author":"Chen","year":"2015","journal-title":"J. Clin. Investig."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1097\/01.ASN.0000088720.61783.19","article-title":"Urinary excretion of monocyte chemoattractant protein-1 in autosomal dominant polycystic kidney disease","volume":"14","author":"Zheng","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ekir.2017.10.004","article-title":"Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients with a High Likelihood of Disease Progression","volume":"3","author":"Messchendorp","year":"2017","journal-title":"Kidney Int. Rep."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1159\/000502999","article-title":"Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors","volume":"50","author":"Messchendorp","year":"2019","journal-title":"Am. J. Nephrol."},{"key":"ref_51","first-page":"969","article-title":"Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease","volume":"32","author":"Grantham","year":"2017","journal-title":"Nephrol. Dial. Transpl."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.34067\/KID.0000000000000525","article-title":"Inflammatory Cytokine Levels in Patients with Autosomal Dominant Polycystic Kidney Disease","volume":"5","author":"Arjune","year":"2024","journal-title":"Kidney 360"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.2215\/CJN.07210520","article-title":"Urinary Soluble CD163 and Disease Activity in Biopsy-Proven ANCA-Associated Glomerulonephritis","volume":"15","author":"Aendekerk","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1681\/ASN.V17980","article-title":"A hereditary model of slowly progressive polycystic kidney disease in the mouse","volume":"1","author":"Takahashi","year":"1991","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1681\/ASN.V10122534","article-title":"Clinical and pathologic findings in two new allelic murine models of polycystic kidney disease","volume":"10","author":"Vogler","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/j.kint.2018.06.025","article-title":"CD8+ T cells modulate autosomal dominant polycystic kidney disease progression","volume":"94","author":"Kleczko","year":"2018","journal-title":"Kidney Int."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e13951","DOI":"10.14814\/phy2.13951","article-title":"Urinary T cells correlate with rate of renal function loss in autosomal dominant polycystic kidney disease","volume":"7","author":"Zimmerman","year":"2019","journal-title":"Physiol. Rep."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:37:32Z","timestamp":1759919852000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,28]]},"references-count":57,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031121"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031121","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,28]]}}}